Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Astrocytoma 8Glioblastoma 5Prostatic Neoplasms 4Neuroectodermal Tumors, Primitive 4Lymphoma, Non-Hodgkin 4Recurrence 3Lung Neoplasms 3Glioma 3Breast Neoplasms 3Oligodendroglioma 2Neurocytoma 2Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Somatostatinoma 1Small Intestine Cancer 1Small Cell Lung Carcinoma 1Sarcoma 1Salivary Gland Neoplasms 1Rhabdoid Tumor 1Pituitary Neoplasms 1Paranasal Sinus Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

tanezumab 1siltuximab 1erenumab 1antineoplaston AS 2-1 1antineoplaston A10 1Saline Solution 1Radiosurgery 1Radiation Dose Hypofractionation 1Protons 1Proton Therapy 1Mn-PyC3A 1Lapatinib 1Hyperspectral Imaging 1HDAC-42 1Bevacizumab 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neurilemmoma × antineoplaston A10 × Clear all
NCT02988726 2017-07-26

Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma

Burzynski Research Institute

Phase 2 Terminated
3 enrolled
CNS

Neurilemmoma, Neurofibroma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡